Neovasc's Reducer Demonstrates Improved Diastolic Function in Patients With Severe Angina
April 22, 2019—Neovasc Inc. announced that findings demonstrating that coronary sinus (CS) narrowing with the use of the company's Reducer device improves diastolic function and relaxation of the heart in patients with refractory angina were published online by Yishay Szekely, MD, et al in International Journal of Cardiology.
According to the company, the study's objective was to evaluate the impact of CS narrowing on stiffness and relaxation abilities of the left ventricle (diastolic function) in patients with myocardial ischemia and severe refractory angina treated with Reducer. The study demonstrated that treatment with Reducer may lead to improvement in diastolic function and echocardiographic parameters of left ventricular relaxation.
The company noted that the results of this trial may preclude the speculation that CS narrowing might adversely affect relaxation of the heart muscle. Additionally, Neovasc advised that the study demonstrated that Reducer not only improved angina status and quality of life of these patients but also resulted in a significant improvement in mean diastolic function.
The observed improvement in the relaxation properties of the heart are likely due to improved blood perfusion to ischemic territories of the heart muscle, which is a known effect of Reducer, stated Neovasc.
The Reducer device received European CE Mark approval for the treatment of refractory angina. The device is not yet approved for commercial use in the United States. The FDA granted Breakthrough Device designation to the Reducer device in October 2018.